Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Open access
Nauck, Michael A., D‘Alessio, David A. · 2022 · Cardiovascular Diabetology

Abstract

Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake. Five clinical trials in type 2-diabetic subjects (SURPASS 1–5) have shown that tirzepatide at 5–15 mg per week reduces both HbA 1c (1.24 to 2.58%) and body weight (5.4–11.7 kg) by amounts unprecedented for a single agent. A sizable proportion of patients (23.0 to 62.4%) reached an HbA 1c of < 5.7% (which is the upper limit of the normal range indicating normoglycaemia), and 20.7 to 68.4% lost more than 10% of their baseline body weight. Tirzepatide was significantly more effective in reducing HbA 1c and body weight than the selective GLP-1 RA semaglutide (1.0 mg per week), and titrated basal insulin. Adverse events related to tirzepatide were similar to what has been reported for selective GLP-1RA, mainly nausea, vomiting, diarrhoea, and constipation, that were more common at higher doses. Cardiovascular events have been adjudicated across the whole study program, and MACE-4 (nonfatal myocardial infarction, non-fatal stroke, cardiovascular death and hospital admission for angina) events tended to be reduced over up to a 2 year-period, albeit with low numbers of events. For none of the cardiovascular events analysed (MACE-4, or its components) was a hazard ratio > 1.0 vs. pooled comparators found in a meta-analysis covering the whole clinical trial program, and the upper bounds of the confidence intervals for MACE were < 1.3, fulfilling conventional definitions of cardiovascular safety. Tirzepatide was found to improve insulin sensitivity and insulin secretory responses to a greater extent than semaglutide, and this was associated with lower prandial insulin and glucagon concentrations. Both drugs caused similar reductions in appetite, although tirzepatide caused greater weight loss. While the clinical effects of tirzepatide have been very encouraging, important questions remain as to the mechanism of action. While GIP reduces food intake and body weight in rodents, these effects have not been demonstrated in humans. Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP. Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-022-01604-7

Cites

Statistics

Figures

Fig. 1 Amino acid sequences of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), the GLP-1 receptor agonist exenatide, and tirzepatide, a GIP/GLP-1 receptor co-agonist. Colours indicate amino acids in the peptide sequence of tirzepatide which correspond to amino acids in the original primary structure of GLP-1 (green), GIP (blue), shared by both GLP-1 and GIP (blue-green), exenatide (orange). Amino acids not related to any of the parent peptides are shown in yellow. Amino-iso-butyric acid (AIB), a non-natural amino acid, is shown in grey with red letters. The primary amino acid sequence of tirzepatide has been taken from [13]; the sequences for human GIP, mammalian GLP-1, and exenatide for comparison are from [22–24]
Fig. 1 Amino acid sequences of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), the GLP-1 receptor agonist exenatide, and tirzepatide, a GIP/GLP-1 receptor co-agonist. Colours indicate amino acids in the peptide sequence of tirzepatide which correspond to amino acids in the original primary structure of GLP-1 (green), GIP (blue), shared by both GLP-1 and GIP (blue-green), exenatide (orange). Amino acids not related to any of the parent peptides are shown in yellow. Amino-iso-butyric acid (AIB), a non-natural amino acid, is shown in grey with red letters. The primary amino acid sequence of tirzepatide has been taken from [13]; the sequences for human GIP, mammalian GLP-1, and exenatide for comparison are from [22–24]CC BY · PubMed Central
Fig. 2 Binding affinity of GIP, GLP-1, and the dual (GIP and GLP-1 receptor) co-agonist tirzepatide (formerly named LY3298176) to human embryonic kidney (HEK 293) cells transfected with human GIP and GLP-1 receptors, and potency in stimulating cyclic adenosine mono-phosphate (cAMP) accumulation. Data have been taken from Coskun et al. 2018 [13] and are expressed as EC50 (effective concentration resulting in half-maximal stimulation) or Ki (inhibitory constant, leading to half-maximal displacement of tracer)
Fig. 2 Binding affinity of GIP, GLP-1, and the dual (GIP and GLP-1 receptor) co-agonist tirzepatide (formerly named LY3298176) to human embryonic kidney (HEK 293) cells transfected with human GIP and GLP-1 receptors, and potency in stimulating cyclic adenosine mono-phosphate (cAMP) accumulation. Data have been taken from Coskun et al. 2018 [13] and are expressed as EC50 (effective concentration resulting in half-maximal stimulation) or Ki (inhibitory constant, leading to half-maximal displacement of tracer)CC BY · PubMed Central
Fig. 3 Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 to 5; [15–19]) clinical trials, all according to the treatment estimand (SURPASS 1–5) or by Bayesian modified intention-to-treat analysis without considering data acquired post-rescue (GPWB). The upper row of panels depicts effects on HbA1c (reduction vs. baseline). The lower row of panels shows effects on body weight (reduction vs. baseline). Asterisks (*) indicate a significant difference (p < 0.05) vs. the respective comparator. Comparators were placebo and dulaglutide (1.5 mg per week) in phase 2 (GPGB), placebo (grey; SURPASS-1 and -5), semaglutide 1.0 mg (orange; SURPASS-2), basal insulin degludec (darker brown; SURPASS-3) and basal insulin glargine U100 (lighter brown; SURPASS-4). Patient numbers per arm are presented in the bottom of the lower panels
Fig. 3 Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 to 5; [15–19]) clinical trials, all according to the treatment estimand (SURPASS 1–5) or by Bayesian modified intention-to-treat analysis without considering data acquired post-rescue (GPWB). The upper row of panels depicts effects on HbA1c (reduction vs. baseline). The lower row of panels shows effects on body weight (reduction vs. baseline). Asterisks (*) indicate a significant difference (p < 0.05) vs. the respective comparator. Comparators were placebo and dulaglutide (1.5 mg per week) in phase 2 (GPGB), placebo (grey; SURPASS-1 and -5), semaglutide 1.0 mg (orange; SURPASS-2), basal insulin degludec (darker brown; SURPASS-3) and basal insulin glargine U100 (lighter brown; SURPASS-4). Patient numbers per arm are presented in the bottom of the lower panelsCC BY · PubMed Central
Fig. 4 Effects of tirzepatide on adjudicated cardiovascular events in SURPASS-4 [18] (A), a clinical trial recruiting subjects at high risk for cardiovascular events, and across the clinical trial program (phases 2 and 3) for tirzepatide [20] (B). MACE: Major adverse cardiovascular events. The line of identity (red, dashed) indicates an equal risk for CV events for tirzepatide and comparator(s). The blue, dashed line marks a hazard ratio of 1.3. An upper bound of the confidence interval for composite endpoints (MACE-3 and MACE-4, but not for individual endpoints) below 1.3 conventionally is interpreted as indicating a cardiovascular risk, which is not significantly elevated in comparison to the comparator(s). Comparators include placebo, insulin degludec, insulin glargine, dulaglutide 1.5 mg/week, and semaglutide 1.0 mg/week (GLP-1 receptor agonists). The numbers of patients at risk and the numbers of events observed are presented. The asterisk indicates a significant difference indirectly inferred from the 95% confidence interval completely being below the line of identity (= 1)
Fig. 4 Effects of tirzepatide on adjudicated cardiovascular events in SURPASS-4 [18] (A), a clinical trial recruiting subjects at high risk for cardiovascular events, and across the clinical trial program (phases 2 and 3) for tirzepatide [20] (B). MACE: Major adverse cardiovascular events. The line of identity (red, dashed) indicates an equal risk for CV events for tirzepatide and comparator(s). The blue, dashed line marks a hazard ratio of 1.3. An upper bound of the confidence interval for composite endpoints (MACE-3 and MACE-4, but not for individual endpoints) below 1.3 conventionally is interpreted as indicating a cardiovascular risk, which is not significantly elevated in comparison to the comparator(s). Comparators include placebo, insulin degludec, insulin glargine, dulaglutide 1.5 mg/week, and semaglutide 1.0 mg/week (GLP-1 receptor agonists). The numbers of patients at risk and the numbers of events observed are presented. The asterisk indicates a significant difference indirectly inferred from the 95% confidence interval completely being below the line of identity (= 1)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 95 · Cited by 407

Research works printed but not linked: 1

  1. Urva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT. Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet. 2022;60(8):1049–59. · DOI

Metadata

Authors
Nauck, M. A., & D‘Alessio, D. A.
Affiliations
St. Josef-Hospital (DE)
Corresponding author
Nauck, Michael A.
Venue
Cardiovascular Diabetology
Published
2022-09-01
Volume
21
Issue
1
Pages
169-169
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4294069033
Cited by
407
References
95
Citations by year
2026: 126 · 2025: 124 · 2024: 85 · 2023: 69 · 2022: 3
FWCI
9.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dokumentenrepositorium der RUB (Ruhr University Bochum) (submittedVersion, cc-by)
Funders
Katholisches Klinikum Bochum gGmbh
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, type 2 diabetes, GLP-1 receptor agonists, semaglutide, glycemic control, weight loss, cardiovascular safety, major adverse cardiovascular events, insulin sensitivity, insulin secretion, glucagon, appetite, obesity
MeSH terms
Glycemic Control, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Body Weight, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Insulin, Meta-Analysis as Topic, Weight Loss, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. https://app.cochat.ai/papers/10.1186/s12933-022-01604-7
The paper
Nauck, M. A., & D‘Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-022-01604-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.